Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1543)	2/27/2008 12:49:57 PM
From: Jibacoa	Respond to of 3722

After dipping below the $1 level earlier this month, YMI is trying to test the resistance at the $1.25 level.<g> The stock is up 5.37% on light volume of 27,000 about 0.16x its ADV bigcharts.marketwatch.com On Feb 13 it announced that its subsidiary, YM BioSciences USA, has enrolled the 1st patient in its PII of nimotuzumab in pediatric patients with recurrent pontine glioma.Nimotuzumab is a humanized monoclonal antibody that targets the EGFR. The stock is trading around 0.7xBV It has been able to trim some its loss in the last 3Qs in spite of lower revenues on the Dec Q The EL for the Yr. ending in June is around $0.40/shr vs. the $0.54 loss in 2007.The short ratio is about 1.5x its ADV The stock remains on the DT coming from its March 2006 H at $6.50 bigcharts.marketwatch.com Bernard